GENE ONLINE|News &
Opinion
Blog

2022-06-02| Trials & Approvals

Sanofi and Sobi Receive Breakthrough Therapy Designation for Hemophilia A Drug

by Reed Slater
Share To

Sanofi, the Paris-based pharmaceutical giant, and its Swedish partner, Sobi, received news that its hemophilia A targeting drug, efanesoctocog alfa, received breakthrough therapy designation from the FDA, pushing it closer to a potential approval date. With new clinical study data, Sanofi hopes to submit efanesoctocog alfa to the FDA for regulatory approval to market the drug commercially. 

 

Tough Competition for Hemophilia A Treatment

 

Hemophilia A is a lifelong, rare blood disorder affecting about 1 in 5,000 males and is exceptionally rare in females. The disorder is characterized by an inability of a person’s blood to clot due to a coagulation factor deficiency. This can result in bleeding episodes that cause pain, joint damage, and even life-threatening hemorrhages. 

Efanesoctocog alfa is a factor VIII therapy which means it creates blood-clotting proteins absent in patients with hemophilia A. Efanesoctocog alfa received orphan drug designation from the FDA in 2017 and fast track designation in 2021. The most recent breakthrough therapy designation is based on data from the Phase 3 EXTEND-1 study, which will also be the basis for Sanofi’s approval submission planned for later this year. 

Even with its momentum behind it, efanesoctocog alfa faces tough competition among long-standing factor VIII therapies on the market. Novo Nordisk’s Novoeight was among the first factor VIII drugs approved to treat hemophilia A in 2013. Since then, several others have followed suit, including, Baxter International’s Obizur in 2014, Genentech’s Hemlibra in 2017, Bayer’s Jivi in 2018, and Wyeth Pharmaceuticals XYNTHA in 2020. Sanofi even owns Eloctate, which was originally approved by the FDA in 2014 under Biogen, however, Sanofi purchased Biogen’s blood disorder-focused company, Bioverativ, in 2018.

 

Related Article: Sanofi’s Trial to Make Cialis Available Over-the-Counter Meets FDA Hold

 

Standing Out Among the Rest

 

With so many available therapies on the market, Sanofi and Sobi had to highlight efanesoctocog alfa’s superior performance over previously approved drugs to meet the criteria for breakthrough therapy designation. To check that box, the two companies say the EXTEND-1 study showed meaningful prevention of bleeds in participants over a 52-week period. Sanofi and Sobi also said that the drug was superior to previous factor VIII replacement therapies in preventing bleed events in intra-patient comparison. 

Global head of research and development at Sanofi, Dr. John Reed, said, “The Breakthrough Therapy designation highlights efanesoctocog alfa’s potential to transform treatment for people with hemophilia A by providing higher protection for longer duration. This potential new class of factor VIII therapy represents how we are boldly advancing science to address unmet needs for the hemophilia community.”

Sanofi and Sobi hope to submit efanesoctocog alfa to the FDA for regulatory approval by the end of 2022. They also hope to publish data from EXTEND-Kids, the pediatric branch of the drug, by 2023.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Walmart To Settle Opioid Lawsuits with $3.1 Billion, U.S. Government Mulls OTC Naloxone
2022-11-15
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
Insilico Makes its Biggest AI Deal Ever with Sanofi for Potential $1.2 Billion
2022-11-09
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!